Luciana Dias Ghiraldi Lopes

Luciana Dias Ghiraldi Lopes

Auto-generated profile, based on publicly available information

Luciana Dias Ghiraldi Lopes

Laboratory of Clinical Virology, State University of Maringá, Maringá, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Future Microbiology
Verified
Journal Article
Closed access
NSNathally C de S Santos
Nathally C de S Santos
RSRegiane B de L Scodro
Regiane B de L Scodro
DLDayane Cb Leal
Dayane Cb Leal
SPSilvia Mt Do Prado
Silvia Mt Do Prado
DMDaniela F Micheletti
Daniela F Micheletti
RCRosilene Cardoso
Rosilene Cardoso
Aim: To evaluate an assay to detect minimum bactericidal concentration (MBC) in Mycobacterium tuberculosis, using as single model rifampicin, isoniazid, levofloxacin (LVX) and linezolid (LNZ) and i...

30 March 2020 in Reviews in Medical Virology
Verified
Journal Article
Closed access
PDF file
FJFernando A. Jorge
Fernando A. Jorge
MTMateus V. Thomazella
Mateus V. Thomazella
DMDeborah de Castro Moreira
Deborah de Castro Moreira
LLLuciana D. G. Lopes
Luciana D. G. Lopes
JTJorge J. V. Teixeira
Jorge J. V. Teixeira
DBDennis Bertolini
Dennis Bertolini

15 April 2021 in Immunotherapy
Verified
Journal Article
Closed access
CMCamila Alves Mota
Camila Alves Mota
JOJully Oyama
Jully Oyama
MMMariana de Souza Terron Monich
Mariana de Souza Terron Monich
ABAline Ávila Brustolin
Aline Ávila Brustolin
JSJoão Vítor Perez de Souza
João Vítor Perez de Souza
TSThais Silveira
Thais Silveira
Aim: Current treatments for leishmaniases are not satisfactory, thus alternatives are needed. We searched for clinical trials with immunotherapeutic approaches for patients with leishmaniasis. Mate...

5 December 2024 in Brazilian Journal of Microbiology
Verified
Journal Article
Closed access
PDF file
LSLéo Shigueki Sato
Léo Shigueki Sato
DMDeborah de Castro Moreira
Deborah de Castro Moreira
SMSonia Kaori Miyamoto
Sonia Kaori Miyamoto
LLLuciana Dias Ghiraldi Lopes
Luciana Dias Ghiraldi Lopes
DBDennis Bertolini
Dennis Bertolini

21 February 2026 in Reviews in Medical Virology
Verified
Journal Article
Open access
HMHeloise Skiavine Madeira
Heloise Skiavine Madeira
ABAline Ávila Brustolin
Aline Ávila Brustolin
MAMarcos Elias da Silva Almeida
Marcos Elias da Silva Almeida
MRMaiara Vanusa Guedes Ribeiro
Maiara Vanusa Guedes Ribeiro
RARaul Gomes Aguera
Raul Gomes Aguera
JTJorge Juarez Vieira Teixeira
Jorge Juarez Vieira Teixeira
No laboratory test performed to date provides an absolute guarantee for detecting infectious agents. Nucleic acid amplification techniques/tests (NAT) associated with serological tests can increase safety and provide greater diagnostic accuracy for patients. We investigated the added safety of NAT technology combined with serological tests for screening blood donors for Hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Data were obtained from a systematic search conducted up until march 30, 2024 in five electronic databases: PubMed, Web of Science, Scopus, Embase , and the Cochrane library . Twenty‐nine studies, published between 1998 and 2023, were included in the review. Notably, HBV infection was predominant among donors with positive NAT results, with 425 cases, including 373 with positive serology and 52 with negative serology. Data from the diagnostic window period (WP) indicated the highest number of HBV infection cases, with 154 reported. Of the 29 included studies, 10 reported cases of occult HBV infection and diagnostic WP infection. Thirteen studies identified donors during the occult HBV infection period, and 17 identified WP cases. Meta‐analyses of positive NAT results following negative serological screening for HBV, HCV, and HIV revealed a significantly pooled frequency ( p < 0.001). Positive NAT results retrieved from donors with negative serological HBV and HCV showed a significantly combined frequency ( p < 0.001), while for HIV occurs the opposite ( p = 0.085). For HBV, HBC and HIV serological tests and NAT‐positive results, the pooled frequency was significantly ( p < 0.001). The findings demonstrate the positive relationship and safety of molecular technology in screening blood donors for HBV, HCV, and HIV using serological tests. Molecular testing remains a valuable tool for detecting and elucidating bloodborne infections.

7 August 2025 in Brazilian Journal of Microbiology
Verified
Journal Article
Closed access
PDF file
LSLéo Shigueki Sato
Léo Shigueki Sato
VFVitória Belucci Frachinconi
Vitória Belucci Frachinconi
DMDeborah de Castro Moreira
Deborah de Castro Moreira
OMOséias da Silva Martinuci
Oséias da Silva Martinuci
LLLuciana Dias Ghiraldi Lopes
Luciana Dias Ghiraldi Lopes
DBDennis Bertolini
Dennis Bertolini